A study from Insilico Medicine said it will present first-in-human data for ISM6331, an AI-designed pan-TEAD inhibitor, at ESMO 2026. The TEAD pathway is implicated in multiple cancers through YAP/TAZ-mediated transcription, and the company’s claim is a rapid move from computational design to early clinical evaluation. In parallel, a new translational study in uveal melanoma used CRISPR-based synthetic lethal screening to pinpoint chromatin co-factors p300 and CBP as essential for YAP-driven transcription in GNAQ-mutant tumors, highlighting a mechanistic dependency that could inform next-generation combination strategies. Together, the updates underscore how AI is compressing target-to-lead timelines while functional genomics continues to refine which molecular nodes are truly actionable in specific tumor genotypes.